These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34802469)

  • 1. Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis.
    Pompsch M; Fisenkci N; Horn PA; Kraemer M; Lindemann M
    Neurol Res Pract; 2021 Nov; 3(1):60. PubMed ID: 34802469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
    Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
    Front Immunol; 2021; 12():796482. PubMed ID: 35111162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.
    Katz JD; Bouley AJ; Jungquist RM; Douglas EA; O'Shea IL; Lathi ES
    Mult Scler Relat Disord; 2022 Jan; 57():103382. PubMed ID: 35158475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
    Achiron A; Mandel M; Dreyer-Alster S; Harari G; Magalashvili D; Sonis P; Dolev M; Menascu S; Flechter S; Falb R; Gurevich M
    Ther Adv Neurol Disord; 2021; 14():17562864211012835. PubMed ID: 34035836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis.
    Achtnichts L; Jakopp B; Oberle M; Nedeltchev K; Fux CA; Sellner J; Findling O
    Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab.
    Gallo A; Capuano R; Donnarumma G; Bisecco A; Grimaldi E; Conte M; d'Ambrosio A; Coppola N; Galdiero M; Tedeschi G
    Neurol Sci; 2021 Sep; 42(9):3523-3526. PubMed ID: 34128150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Immune Response Profiles to SARS-CoV-2 Vaccination and Infection in People with Multiple Sclerosis on Anti-CD20 Therapy.
    Woopen C; Dunsche M; Al Rahbani GK; Dillenseger A; Atta Y; Haase R; Raposo C; Pedotti R; Ziemssen T; Akgün K
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis.
    van Kempen ZLE; Hogenboom L; Toorop AA; Steenhuis M; Stalman EW; Kummer LYL; van Dam KPJ; Bloem K; Ten Brinke A; van Ham SM; Kuijpers TW; Wolbink GJ; Loeff FC; Wieske L; Eftimov F; Rispens T; Strijbis EMM; Killestein J;
    Ann Neurol; 2023 Jan; 93(1):103-108. PubMed ID: 36250739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine.
    Conway S; Saxena S; Baecher-Allan C; Krishnan R; Houtchens M; Glanz B; Saraceno TJ; Polgar-Turcsanyi M; Bose G; Bakshi R; Bhattacharyya S; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Paul A; Weiner HL; Healy BC; Chitnis T
    Mult Scler J Exp Transl Clin; 2023; 9(2):20552173231165196. PubMed ID: 37057191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
    Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
    Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients.
    Guerrera G; Mandelli A; Finardi A; Orrico M; D'Orso S; Picozza M; Noviello M; Beretta V; Bonetti B; Calabrese M; Marastoni D; De Rossi N; Capra R; Salvetti M; Buscarinu MC; Inglese M; Uccelli A; Moiola L; Raposo C; Muros-Le Rouzic E; Pedotti R; Filippi M; Bonini C; Battistini L; Borsellino G; Furlan R
    Mult Scler; 2022 Oct; 28(12):1937-1943. PubMed ID: 35723265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
    van Kempen ZLE; Wieske L; Stalman EW; Kummer LYL; van Dam PJ; Volkers AG; Boekel L; Toorop AA; Strijbis EMM; Tas SW; Wolbink GJ; Löwenberg M; van Sandt C; Ten Brinke A; Verstegen NJM; Steenhuis M; Kuijpers TW; van Ham SM; Rispens T; Eftimov F; Killestein J;
    Mult Scler Relat Disord; 2022 Jan; 57():103416. PubMed ID: 34847379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters.
    Conte WL; Golzarri-Arroyo L
    Mult Scler Relat Disord; 2022 Jul; 63():103905. PubMed ID: 35661563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty
    Held J; Esse J; Tascilar K; Steininger P; Schober K; Irrgang P; Alsalameh R; Tenbusch M; Seggewies C; Bogdan C
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
    Speich B; Chammartin F; Smith D; Stoeckle MP; Amico P; Eichenberger AL; Hasse B; Schuurmans MM; Müller T; Tamm M; Dickenmann M; Abela IA; Trkola A; Hirsch HH; Manuel O; Cavassini M; Hemkens LG; Briel M; Mueller NJ; Rauch A; Günthard HF; Koller MT; Bucher HC; Kusejko K;
    Trials; 2021 Oct; 22(1):724. PubMed ID: 34674742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report.
    Mado H; Kubicka-Bączyk K; Adamczyk-Sowa M
    J Int Med Res; 2021 Sep; 49(9):3000605211044378. PubMed ID: 34528472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients.
    Melin J; Svensson MK; Albinsson B; Winqvist O; Pauksens K
    BMC Immunol; 2021 Oct; 22(1):70. PubMed ID: 34666683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of Induction of RBD-Specific Neutralizing Antibodies despite Repeated Heterologous SARS-CoV-2 Vaccination Leading to Seroconversion and Establishment of T Cell-Specific Memory in a Patient in Remission of Multiple Myeloma.
    Kratzer B; Trapin D; Gattinger P; Oberhofer T; Sehgal ANA; Waidhofer-Söllner P; Rottal A; Körmöczi U; Grabmeier-Pfistershammer K; Kopetzky GH; Tischer F; Valenta R; Pickl WF
    Vaccines (Basel); 2022 Feb; 10(3):. PubMed ID: 35335006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.